Business Context and Reporting Period
This Form 8-K was filed by Inpixon (trading symbol: INPX) on November 26, 2019. The filing reports a material definitive agreement entered into on the same date between the Company and Iliad Research and Trading, L.P. ("Iliad"), a significant holder of the Company's debt.
Key Financial Metrics and Transaction Details
- Debt Conversion: The Company agreed to exchange a partitioned portion of a promissory note for common stock.
- Principal Amount Converted: $125,000.
- Shares Issued: 2,500,000 shares of Common Stock.
- Effective Price Per Share: $0.05.
- Outstanding Debt to Iliad (Original Note): $669,748.65 as of November 26, 2019 (prior to the $125,000 reduction).
- Other Outstanding Debt to Iliad and Affiliates:
- Note issued Sept 17, 2019: ~$963,000 (as of Oct 27, 2019).
- Chicago Venture Partners, L.P. (Iliad affiliate): ~$9.8 million (as of Oct 27, 2019).
- St. George Investments LLC (Iliad affiliate): ~$952,500 (as of Nov 26, 2019).
- Total Outstanding Common Stock: 96,689,581 shares (including the newly issued shares).
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or revenue/profit metrics for a prior period. The primary material change is the reduction of debt obligations by $125,000 and the corresponding increase in outstanding common stock by 2,500,000 shares. The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Guidance, Outlook, and Risks
- Transaction Mechanics: Shares were to be delivered on or before November 27, 2019. The exchange is contingent upon Iliad surrendering the partitioned note once shares are approved and held by their brokerage firm for public resale.
- Regulatory Exemption: The issuance was unregistered, relying on Section 3(a)(9) of the Securities Act of 1933 as an exchange of securities with no additional consideration or commissions paid.
- Capital Structure: The Company holds various other securities including Series 4 and Series 5 Convertible Preferred Stock and warrants exercisable at $3.33 and $0.2775 per share.
- Management Commentary: No specific outlook or forward-looking guidance is provided in this filing.
Investor Verification Checklist
- Verify the final settlement of the 2,500,000 shares and the corresponding reduction of the $125,000 note balance.
- Assess the total exposure to Iliad and its affiliates, which exceeds $11.7 million in outstanding notes as of late October/November 2019.
- Review the dilution impact of the 2,500,000 new shares on existing shareholders.
- Confirm the status of the remaining debt obligations and any potential for further debt-to-equity conversions.